Vinci Pharmaceuticals Inc. Closes More Than $8 Million Series A Financing to Advance EPIPLANT™ Drug Delivery Platform

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Vinci-Pharmaceuticals

More Like This

PR Newswire associated0

EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services

PR Newswire associated0

VentureMed Group Closes $28M Series C Funding to Accelerate Commercial Adoption and Expand Indications for the FLEX VPTM System

PR Newswire associated0

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PR Newswire associated0

Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver

PR Newswire associated0

Elicit Plant Announces €45 Million Investment Round to Accelerate Global Expansion

(Graphic: Business Wire)

4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing

PR Newswire associated0

Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference